Immunoneutralization of CCR7 or CCL21 with monoclonal antibodies abrogated pulmonary remodeling in CB-17-SCID/bg mice that received IPF fibroblasts, highlighting the contribution of CCL21 to IPF pathogenesis [99] and suggesting the possibility of CCL21 as an attractive target in IPF clinical treatment [99]. The gene discussed is CCL21; the disease is idiopathic pulmonary fibrosis.